MRC PHRU Medical Statistician
Charlie is a Medical Statistician within both the Renal Studies Group and Vascular Overviews Group at the Clinical Trials Service Unit & Epidemiology Studies Unit (CTSU). He joined CTSU in 2015 after working as an analyst within the NHS using routine healthcare data. Charlie completed his undergraduate degree in Economics at the University of East Anglia and MSc in Economics at Bristol University. His current research interests include the use and application of routine healthcare data within observational studies and randomized clinical trials.
He is also currently undertaking a part-time DPhil within the CTSU funded by the MRC Hubs for Trials Methodology Research (MRC HTMR). Charlie aims to investigate whether routine healthcare data can be used as the primary source of follow-up for clinical trials.
Can routine healthcare data be used to efficiently and reliably follow-up participants in renal trials? Analyses using linked data from 2 large renal trials.
Dr Natalie Staplin, Dr Will Herrington, Professor Martin Landray and Professor Colin Baigent
Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
MAFHAM M. et al, (2023), Heart
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
HERRINGTON W. et al, (2023), Kidney International Reports
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: firstname.lastname@example.org None. and RECOVERY Collaborative Group None., (2023), Lancet (London, England), 401, 1499 - 1507
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368